08:15
Welcome address
08:30

SESSION 2 – MYELOID MALIGNANCIES

  • 08.30 The place of Haplo-HSCT in myeloid malignancies in Europe A. Nagler, Tel Hashomer, Israel
  • 09.00 Haplo HSCT for AML R. Devillier, Marseille, France
  • 09.30 Acute leukemia relapse after Allo-HSCT: new insights in prevention and treatment I. Gojo, Baltimore, USA
  • 10.00 Haplo-HSCT for MDS D. Blaise, Marseille, France
10:30
Coffee break & exhibition visit
11:00

SESSION 3 – ALL

  • 11.00 R/R ALL best approach? Monoclonal antibodies N. Vey, Marseille, France
  • 11.30 R/R ALL best approach? Car T-cells J. Gauthier, Seattle, USA
  • 12.00 Discussion
12:00
Lunch & exhibition visit
13:30

SESSION 4 – UPDATE ON HAPLO

  • 13.30 Recent updates in Beijing Haplo-HSCT protocol X. J. Huang, Beijing, China
  • 14.00 Post-Transplant Cyclosphosphamide: GVL without GVHD? B. Andersson, Houston, USA
  • 14.30 Long Term Follow-up and care B, Savani Nashville, USA
  • 15.00 Sequential targeted myeloablation for Myeloid malignancies B, Andersson Houston, USA
  • 15.30 Discussion
15:45

SESSION 5 – CAR T-CELLS (1)

  • 15.45 Present status of Car T-cells in Europe C. Chabannon, Marseille, France
  • 16.15 Car T-cells complications I. Yakoub-Agha, Lille, France
16:45
Coffee break & exhibition visit
17:15

SESSION 6 – CAR T CELLS (2)

  • 17.15 Haplo-HSCT as consolidation of Car T-cells treatment. H. Huang, Hangzhou, China
  • 17.45 Car T-cells for multiple myeloma M. Mohty, Paris, France
  • 18.15 Car T-cells: the Barcelona experience A. Urbano-Ispizua, Barcelona, Spain
  • 18.45 Can cellular immunotherapy be brought to patients living far from academic medical centers? F. Petersen, Boise, USA
20:30
Congress diner
Top